Aliases & Classifications for Calcinosis

MalaCards integrated aliases for Calcinosis:

Name: Calcinosis 12 28 51 41 14 69
Pathologically Calcified Structure 12
Pathologic Calcification 12

Classifications:



External Ids:

Disease Ontology 12 DOID:182
MeSH 41 D002114
NCIt 46 C3672
UMLS 69 C0006663

Summaries for Calcinosis

Disease Ontology : 12 A calcium metabolism disease that is the result of the formation of calcium deposits in any soft tissue.

MalaCards based summary : Calcinosis, also known as pathologically calcified structure, is related to tumoral calcinosis, hyperphosphatemic, familial and tumoral calcinosis, normophosphatemic, familial. An important gene associated with Calcinosis is SAMD9 (Sterile Alpha Motif Domain Containing 9), and among its related pathways/superpathways is Endochondral Ossification. The drugs Alendronate and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and heart, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 72 Calcinosis is the formation of calcium deposits in any soft... more...

Related Diseases for Calcinosis

Diseases related to Calcinosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 211)
# Related Disease Score Top Affiliating Genes
1 tumoral calcinosis, hyperphosphatemic, familial 34.4 FGF23 GALNT3 KL
2 tumoral calcinosis, normophosphatemic, familial 32.9 CALCA GALNT3 RGL2 SAMD9 SAMD9L
3 familial tumoral calcinosis 32.3 FGF23 GALNT3 KL PHEX RGL2 SAMD9
4 hyperphosphatemia 30.4 FGF23 GALNT3 KL MGP
5 hypervitaminosis d 30.0 FGF23 GALNT3 KL
6 hyperostosis 29.9 ANKH FGF23 GALNT3 KL
7 hyperparathyroidism 29.8 CALCA FGF23 PHEX
8 secondary hyperparathyroidism of renal origin 29.2 CALCA FGF23
9 pseudoxanthoma elasticum 29.2 ANKH ENPP1 MGP SPP1
10 osteoporosis 27.9 AHSG CALCA FGF23 KL MGP SPARC
11 crest syndrome 11.8
12 basal ganglia calcification, idiopathic, 1 11.6
13 basal ganglia calcification, idiopathic, childhood-onset 11.5
14 mandibuloacral dysplasia with type a lipodystrophy 11.5
15 dermatomyositis 11.4
16 scleroderma, familial progressive 11.3
17 nephrocalcinosis 11.2
18 primary familial brain calcification 11.0
19 familial idiopathic basal ganglia calcification 11.0
20 reynolds syndrome 11.0
21 cole disease 11.0
22 diffuse idiopathic skeletal hyperostosis 10.8
23 tracheal calcification 10.5 FGF23 KL
24 childhood type dermatomyositis 10.3
25 opsismodysplasia 10.3 FGF23 PHEX
26 prolapse of female genital organ 10.3 LMNA SPARC
27 enthesopathy 10.3 FGF23 PHEX
28 papillary cystadenocarcinoma 10.3 SPARC SPP1
29 hypercementosis 10.3 ENPP1 SPP1
30 oncogenic osteomalacia 10.3 FGF23 PHEX
31 secondary hypertrophic osteoarthropathy 10.2 CALCA GALNT3
32 hypophosphatemic rickets, autosomal dominant 10.2 FGF23 GALNT3 PHEX
33 cervicitis 10.2
34 hypophosphatemic rickets, x-linked dominant 10.2 FGF23 KL PHEX
35 epidermolysis bullosa simplex with muscular dystrophy 10.2 AHSG LMNA
36 adamantinoma of long bones 10.2 SPARC SPP1
37 autosomal recessive hypophosphatemic rickets 10.1 ENPP1 FGF23 PHEX
38 osseous heteroplasia, progressive 10.1 ENPP1 SPARC
39 hypophosphatemic rickets, x-linked recessive 10.1 ENPP1 FGF23 PHEX
40 arteriosclerosis 10.1 KL MGP SPP1
41 hypophosphatemia 10.1 ENPP1 FGF23 PHEX
42 rickets 10.1 ENPP1 FGF23 PHEX
43 lupus erythematosus 10.1
44 bone giant cell tumor 10.1 CALCA SPP1
45 amyloid tumor 10.1 CALCA SPARC
46 adult dermatomyositis 10.0
47 fibrous dysplasia 10.0 CALCA FGF23 SPARC
48 hypophosphatasia 10.0 ENPP1 PHEX
49 systemic lupus erythematosus 10.0
50 phosphorus metabolism disease 10.0 FGF23 GALNT3 KL PHEX

Graphical network of the top 20 diseases related to Calcinosis:



Diseases related to Calcinosis

Symptoms & Phenotypes for Calcinosis

MGI Mouse Phenotypes related to Calcinosis:

43 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.24 MGP SPP1 PHEX LMNA SPARC ENPP1
2 homeostasis/metabolism MP:0005376 10.21 SPP1 MGP PHEX SAMD9L LMNA SPARC
3 cardiovascular system MP:0005385 10.13 LMNA MGP SPP1 KL ANKH GALNT3
4 hematopoietic system MP:0005397 10.11 SPARC SPP1 KL PHEX SAMD9L LMNA
5 immune system MP:0005387 10.1 SPP1 KL PHEX SAMD9L LMNA SPARC
6 craniofacial MP:0005382 10.05 SPP1 PHEX LMNA SPARC KL ANKH
7 integument MP:0010771 9.97 SPP1 SAMD9L LMNA SPARC ENPP1 KL
8 hearing/vestibular/ear MP:0005377 9.95 PHEX LMNA ENPP1 KL AHSG ANKH
9 limbs/digits/tail MP:0005371 9.92 PHEX LMNA SPARC KL FGF23 AHSG
10 muscle MP:0005369 9.86 SPP1 MGP LMNA ENPP1 KL AHSG
11 renal/urinary system MP:0005367 9.76 SPP1 MGP PHEX LMNA ENPP1 KL
12 respiratory system MP:0005388 9.43 LMNA MGP SPP1 KL ANKH FGF23
13 skeleton MP:0005390 9.36 SPP1 MGP PHEX LMNA SPARC ENPP1

Drugs & Therapeutics for Calcinosis

Drugs for Calcinosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 316)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alendronate Approved Phase 4,Phase 2 121268-17-5, 66376-36-1 2088
2
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
3
Zinc Approved, Investigational Phase 4,Phase 2 7440-66-6 32051 23994
4
Fluvastatin Approved Phase 4 93957-54-1 1548972
5
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 3 122320-73-4 77999
6
Sevelamer Approved Phase 4,Phase 3,Phase 2 52757-95-6, 152751-57-0 3085017
7
Everolimus Approved Phase 4 159351-69-6 6442177
8
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 6436030 5284616
9
Ethanol Approved Phase 4,Phase 3 64-17-5 702
10
Calcium acetate Approved, Investigational Phase 4,Phase 3 62-54-4
11
Methyltestosterone Approved Phase 4 58-18-4 6010
12
Testosterone Approved, Investigational Phase 4 58-22-0 6013
13
Dalteparin Approved Phase 4 9005-49-6
14
Denosumab Approved Phase 4,Phase 3,Phase 2 615258-40-7
15
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
16
Mycophenolic acid Approved Phase 4 24280-93-1 446541
17
Apixaban Approved Phase 4 503612-47-3 10182969
18
Warfarin Approved Phase 4 81-81-2 54678486 6691
19
Adenosine Approved, Investigational Phase 4 58-61-7 60961
20
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
21
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 471-34-1
22
Simvastatin Approved Phase 4 79902-63-9 54454
23
Amlodipine Approved Phase 4 88150-42-9 2162
24
Phenprocoumon Approved, Investigational Phase 4 435-97-2 54680692 9908
25
Rivaroxaban Approved Phase 4 366789-02-8
26 fluindione Approved, Investigational Phase 4 957-56-2
27
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
28
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
29
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
30
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
31
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
32
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
33
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 2 67-97-0 10883523 5280795 6221
34
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 1 50-14-6 5280793
35
Menadione Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-27-5 4055
36
Phytonadione Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 84-80-0 5284607 4812
37
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1406-16-2
38
Calcitriol Approved, Nutraceutical Phase 4,Phase 2 32222-06-3 5280453 134070
39
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 77-92-9 311
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
41
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2 59-67-6 938
42
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2 98-92-0 936
43 Antifibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
46 Coagulants Phase 4,Phase 3,Phase 2,Phase 1
47 Ergocalciferols Phase 4,Phase 2,Phase 1
48 Hemostatics Phase 4,Phase 3,Phase 2,Phase 1
49 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
50 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 414)

# Name Status NCT ID Phase Drugs
1 Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients Unknown status NCT01101698 Phase 4 Vitamin K2+10μg cholecalciferol;Vitamin D
2 Alendronate for Vascular Calcification in Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
3 The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus Unknown status NCT02418884 Phase 4 rosuvastatin
4 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4 pioglitazone
5 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
6 A Study of Ferric Citrate to Improve Inflammation and Lipid Levels Unknown status NCT02661295 Phase 4 Ferric Citrate
7 Fluvastatin AmelIorates aTHerosclerosis Study Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
8 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
9 How Bone is Made in Children Receiving Dialysis Unknown status NCT01799317 Phase 4 Vitamin D2
10 TRANSFORM OCT TRiple Assessment of Neointima Stent FOrmation to Reabsorbable polyMer With Optical Coherence Tomography Unknown status NCT01972022 Phase 4
11 Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions Unknown status NCT00640744 Phase 4 Atorvastatin
12 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
13 The Role Of FGF23, Klotho, And Sclerostin In Kidney Stone Formers Unknown status NCT01526304 Phase 4
14 Risk Factors for Vascular Calcifications in Hemodialysis Patients: to What Extent is Vitamin K2 Deficiency Involved? Completed NCT02876354 Phase 4 Menaquinone
15 Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease Completed NCT00395382 Phase 4 Alendronate;Placebo
16 Can Alendronate Suppress Calcification and Improve Bone Density in Chronic Peritoneal Dialysis Patients? Completed NCT00261625 Phase 4 alendronate
17 Vitamin D and Coronary Calcification Study Completed NCT00752102 Phase 4 Calcitriol (Rocaltrol®);Paricalcitol
18 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque Completed NCT02090075 Phase 4 apixaban;warfarin
19 CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
20 ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Completed NCT00379899 Phase 4 cinacalcet
21 Parathyroidectomy in Endstage Renal Disease Completed NCT00745719 Phase 4
22 Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients Completed NCT00745225 Phase 4 Pioglitazone;placebo comparator
23 The XLIMUS-DES in Very Complex Lesions Completed NCT02360020 Phase 4
24 Multiple Interventions Related to Dialysis Procedures in Order to Reduce Cardiovascular Morbidity and Mortality in HD Patients(EGESTUDY) Completed NCT00295191 Phase 4
25 Sevelamer, Fetuin-A and Endothelial Dysfunction in CKD Completed NCT00486772 Phase 4 Sevelamer (Renagel), calcium acetate (Phos-ex)
26 Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD) Completed NCT01135615 Phase 4 Sevelamer;calcium acetate
27 Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D) Completed NCT01019486 Phase 4 Regadenoson myocardial perfusion imaging;Regadenoson MRI myocardial blood flow
28 Effect of Atorvastatin on Bone-vascular Axis Completed NCT02342015 Phase 4 Atorvastatin
29 Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol Completed NCT01748396 Phase 4 Calcitriol;Calcium Carbonate
30 Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes Completed NCT00471549 Phase 4 Statin (simvastatin)
31 REmoval of Free Light Chains. A COmpaRison of Three Different dialyzERs Completed NCT02950389 Phase 4
32 Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism Completed NCT01143987 Phase 4 Cinacalcet
33 Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure Completed NCT00124969 Phase 4 Amlodipine;Placebo
34 TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST Completed NCT02366975 Phase 4 Testosterone gel 2%
35 Prospective Study of Efficacy of Intra-muscular Vitamin D3 in Tropical Calcific Pancreatitis Completed NCT00956839 Phase 4 Vitamin D3 (Cholecalciferol)
36 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
37 Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level Completed NCT01101113 Phase 4 cinacalcet;control
38 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Completed NCT01939977 Phase 4 Paricalcitol;Calcifediol
39 Comparison of Four and Eight Hours Dialysis Sessions in Thrice Weekly Hemodialysis Completed NCT00413803 Phase 4
40 Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients Recruiting NCT02610933 Phase 4 rivaroxaban
41 Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation Recruiting NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
42 Effect of Vitamin D3 Supplementation on Arterial and Bone Remodeling in Chronic Kidney Disease Patients Recruiting NCT02999204 Phase 4 Vitamin D3
43 Assessment of Osteoblastic Activity With 18F-Fluoride in Aortic Bioprosthesis Structural Valve Dysfunction (SVD) Recruiting NCT03015818 Phase 4
44 Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium Recruiting NCT02376010 Phase 4 rivaroxaban;Warfarin
45 Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms Recruiting NCT02252367 Phase 4 Tadalafil
46 Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification Active, not recruiting NCT02066662 Phase 4 Rivaroxaban or Marcumar
47 Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis Active, not recruiting NCT02598635 Phase 4 Cholecalciferol;Placebo
48 Intravenous Paricalcitol in Chronic Hemodialysis Patients Active, not recruiting NCT03023748 Phase 4 Intravenous Paricalcitol
49 Efficacy and Tolerance of Ultrasound-guided Needling and Lavage of Calcific Tendinitis of the Rotator Cuff Performed With or Without Subacromial Corticosteroid Injection Active, not recruiting NCT02403856 Phase 4 Sodium Chloride 0.9%;Methylprednisolone acetate
50 The PARTNER TRIAL - Post Approval Study Part II Active, not recruiting NCT02184442 Phase 4

Search NIH Clinical Center for Calcinosis

Cochrane evidence based reviews: calcinosis

Genetic Tests for Calcinosis

Genetic tests related to Calcinosis:

# Genetic test Affiliating Genes
1 Calcinosis 28

Anatomical Context for Calcinosis

MalaCards organs/tissues related to Calcinosis:

38
Kidney, Bone, Heart, Breast, Endothelial, Thyroid, Brain

Publications for Calcinosis

Articles related to Calcinosis:

(show top 50) (show all 734)
# Title Authors Year
1
Secondary Calcinosis of the Foot. ( 29292317 )
2018
2
MAPnckeberg medial calcinosis of the infraorbital arteries: a first case report. ( 29248421 )
2018
3
Systemic Calcinosis in NXP2-Dermatomyositis. ( 29319550 )
2018
4
Calcinosis cutis universalis in systemic sclerosis. ( 29451139 )
2018
5
Lethal Visceral Calcinosis in Fulminant Hypercalcemic Crisis. ( 29093412 )
2018
6
Enzootic calcinosis in horses grazing Solanum glaucophyllum in Argentina. ( 29202673 )
2018
7
Asymmetric Calcinosis in an Adult Patient With Antisynthetase Syndrome. ( 29319552 )
2018
8
Calcinosis Cutis: WOC Nurse Management. ( 29300294 )
2018
9
Characterization of a Pseudoxanthoma elasticum-like patient with coagulation deficiency, cutaneous calcinosis and GGCX compound heterozygosity. ( 29175035 )
2018
10
Added value of newer optical coherence tomography technologies in hyperphosphatemic familial tumoural calcinosis. ( 29426463 )
2018
11
Dystrophic calcinosis cutis within burns, successfully treated with excision and secondary intention wound healing. ( 29430689 )
2018
12
Idiopathic Calcinosis Cutis Universalis Treated Successfully with Oral Diltiazem-A Case Report. ( 28771811 )
2017
13
Invited Commentary: Calcinosis cutis and renal disease: an evolving story. ( 28670092 )
2017
14
CALCINOSIS CIRCUMSCRIPTA IN A COHORT OF RELATED JUVENILE AFRICAN LIONS (PANTHERA LEO). ( 28920787 )
2017
15
Cutaneous calcinosis in a patient with limited scleroderma: CREST Syndrome. ( 29308290 )
2017
16
Anarthria in a patient with bilateral striopallidodentate calcinosis. ( 28879917 )
2017
17
Severe Calcinosis in Limited Cutaneous Systemic Sclerosis. ( 28824081 )
2017
18
Submucosal Colonic Masses in a Patient With Familial Tumoral Calcinosis. ( 28381848 )
2017
19
Hyperphosphatemic Tumoral Calcinosis after Total Knee Arthroplasty. ( 29123932 )
2017
20
Bilateral striopallidodentate calcinosis associated with SjAPgren's syndrome and IgDI> monoclonal gammopathy of undetermined significance. ( 29183861 )
2017
21
Extraosseous Calcification of the Esophagus: Clinicopathologic Correlates of Esophageal Mucosal Calcinosis. ( 28932755 )
2017
22
Tumoral calcinosis in the cervical spine: a case report and review of the literature. ( 29073937 )
2017
23
Scrotal calcinosis: two case reports. ( 29101926 )
2017
24
Calcified Keratoacanthoma with Tumoral Calcinosis in a 10-year-old Boy: A mere Co-incidence? ( 29263542 )
2017
25
Mammography Findings of Breast Calcinosis in a Patient With Dermatomyositis. ( 28816763 )
2017
26
Are there risk factors for scleroderma-related calcinosis? ( 28722530 )
2017
27
Extensive Dystrophic Calcinosis Cutis: A Severe Complication of Polymyositis/Systemic Sclerosis Overlap Syndrome. ( 28926465 )
2017
28
Idiopathic Tumoral Calcinosis - Rare Clinico Pathological Entity: A Report of Two Cases. ( 28764177 )
2017
29
Extensive calcinosis in adult dermatomyositis. ( 28396153 )
2017
30
Efficacy of intralesional sodium thiosulfate injections for disabling tumoral calcinosis: Two cases. ( 28779847 )
2017
31
Metastatic calcinosis cutis in end-stage renal disease. ( 28670091 )
2017
32
Clinical and radiological improvement in idiopathic calcinosis cutis with topical 25% sodium metabisulfite. ( 29076152 )
2017
33
Dermoscopy is useful for the diagnosis of milia-like idiopathic calcinosis cutis. ( 28726314 )
2017
34
Calcinosis Cutis ( 28846311 )
2017
35
Uremic Tumoral Calcinosis Resolved by Improvements in Hyperphosphatemia. ( 28626193 )
2017
36
Quartz Crystal Microbalance Assay of Clinical Calcinosis Samples and Their Synthetic Models Differentiates the Efficacy of Chelation-Based Treatments. ( 28752990 )
2017
37
Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). ( 28934971 )
2017
38
Lack of Response to Intravenous Sodium Thiosulfate in Three Cases of Extensive Connective Tissue Disease-Associated Calcinosis Cutis. ( 28667747 )
2017
39
The idiopathic localized tumoral calcinosis: the "chicken wire" radiographic pattern. ( 28828127 )
2017
40
Big Gain; No Pain: Tumoral Calcinosis. ( 28923522 )
2017
41
Avid<sup>18</sup>F-FDG Uptake in Idiopathic Tumoral Calcinosis Mimicking Lymph Node Metastasis. ( 29236066 )
2017
42
Facial calcinosis cutis in a patient with systemic lupus erythematosus: A case report of tissue injury owing to photosensitivity as the cause of dystrophic calcification. ( 28936472 )
2017
43
Metastatic Calcinosis of Aortic Valve Secondary to Renal Failure Mimicking Infective Endocarditis. ( 27738529 )
2016
44
Intradural tumoral calcinosis of the foramen magnum region: A case report. ( 27728984 )
2016
45
Hartsfield syndrome associated with a novel heterozygous missense mutation in FGFR1 and incorporating tumoral calcinosis. ( 27170295 )
2016
46
Central cord syndrome in a patient with systemic sclerosis and cervical calcinosis: case report and review of literature. ( 28053731 )
2016
47
Nontraumatic tumoral calcinosis. ( 27663758 )
2016
48
Tumoral Calcinosis: An Uncommon Cause for a Mass in a Reconstructed Breast. ( 27579225 )
2016
49
Tumoral calcinosis of the cervical spine in a dialysis patient. Case report and review of the literature. ( 28012693 )
2016
50
Scrotal calcinosis. ( 27920100 )
2016

Variations for Calcinosis

Expression for Calcinosis

Search GEO for disease gene expression data for Calcinosis.

Pathways for Calcinosis

Pathways related to Calcinosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.61 ENPP1 MGP SPP1

GO Terms for Calcinosis

Cellular components related to Calcinosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 AHSG CALCA ENPP1 FGF23 KL SPARC
2 extracellular region GO:0005576 9.23 AHSG CALCA ENPP1 FGF23 KL MGP

Biological processes related to Calcinosis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.88 CALCA FGF23 KL SPP1
2 skeletal system development GO:0001501 9.73 AHSG ANKH PHEX
3 ossification GO:0001503 9.69 AHSG MGP SPARC
4 cellular protein metabolic process GO:0044267 9.67 AHSG CALCA FGF23 SPP1
5 fibroblast growth factor receptor signaling pathway GO:0008543 9.65 FGF23 GALNT3 KL
6 negative regulation of insulin receptor signaling pathway GO:0046627 9.57 AHSG ENPP1
7 phosphate-containing compound metabolic process GO:0006796 9.55 ENPP1 FGF23
8 response to vitamin D GO:0033280 9.54 PHEX SPP1
9 negative regulation of bone mineralization GO:0030502 9.52 AHSG FGF23
10 cellular response to vitamin D GO:0071305 9.49 FGF23 PHEX
11 endosomal vesicle fusion GO:0034058 9.46 SAMD9 SAMD9L
12 cellular phosphate ion homeostasis GO:0030643 9.43 ENPP1 FGF23
13 cellular response to parathyroid hormone stimulus GO:0071374 9.4 FGF23 PHEX
14 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.32 FGF23 KL
15 inorganic diphosphate transport GO:0030505 9.26 ANKH ENPP1
16 response to sodium phosphate GO:1904383 9.16 FGF23 PHEX
17 biomineral tissue development GO:0031214 9.13 ENPP1 PHEX SPP1
18 regulation of bone mineralization GO:0030500 9.02 AHSG ANKH ENPP1 FGF23 MGP

Molecular functions related to Calcinosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix binding GO:0050840 9.16 SPARC SPP1
2 fibroblast growth factor receptor binding GO:0005104 8.96 FGF23 KL
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.8 FGF23 KL RGL2

Sources for Calcinosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....